Watch the best Europeans in biotech to grow. Hosted by Philip Hemme. 15k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, and Sander van Deventer @VectorY & Forbion. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Dominik Schumacher, Tubulis đ©đȘ | Founder-led ADC Biotech âïž | E19
1:08:38
1:08:38
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:08:38
Weâre in Munich đ©đȘ with a âtrueâ biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis.We talked about building a champion ADC biotech, the super hot ADC sphere, and the differâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Otello Stampacchia, Omega Funds đźđč | M&A, Boston & Pasta | E18
1:02:46
1:02:46
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:02:46
Weâre in Boston đșđž with one of the top VCs, Otello Stampacchia of Omega Funds.We talked about the highest competitive tension in biopharma now that he has ever seen. We also talked about his career, especially the challenges and opportunities he had from moving to Boston over 15 years ago.đ TRANSCRIPTRead the full transcript here: https://flot.bio/âŠ
…
continue reading
Weâre in San SebastiĂĄn đȘđž with one of the top VCs in Europe, Christina Takke from V-Bio Ventures. We talk about her path to get to the top and the benefits of gender diversity for both investing and European biotech as a whole. We also talk about her investment in Argenx when it was only three employees and the venture creation had dropped since 20âŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Naveed Siddiqi, Novo Holdings đŹđ§đ©đ° | Sharp Macro View of đȘđș Biotech | E16
46:16
Weâre in San SebastiĂĄn đȘđž with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings. We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. Iâve known him since he was a partner at Andera. He is a sâŠ
…
continue reading
Weâre in Hannover đ©đȘ with the founder and CEO of Cardior, Claudia Ulbrich We talked about Cardiorâs recent âŹ1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname âFrau Biotechâ. đ ABOUT THE SPEAKER Claudia has been founding biotechs since the â90s. She founded her first biotech company, LipoNovaâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Bahija Jallal, Immunocore đŹđ§ | Commercial, Diversity, and AI | E14
1:15:45
1:15:45
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:15:45
Weâre super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gendeâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Edwin Moses | How to build large biotech platforms | E13
1:26:40
1:26:40
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:26:40
Weâre in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow. đ ABOUTâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Jens Nielsen, BII | How to make translation of life science research work | E12
1:18:34
1:18:34
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:18:34
Weâre in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist entrepreneurs face and the drawbacks of Novo financing mâŠ
…
continue reading
Weâre in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and whatâs missing in gene therapy. đ ABOUT THE SPEAKERSander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the âŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Thomas Clozel, Owkin | What does AI Biotech really mean | E10
1:20:13
1:20:13
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:20:13
In an online special, weâre interviewing Thomas Clozal, the co-founder and CEO of Owkin. We talk about scaling AI in biotech and how it feels to be the child of billionaire biotech parents.đ ABOUT THE SPEAKERThomas founded Owkin in 2016 and I first met him in 2017. At that time, Owkin was still a baby and I wasnât sure where it would go. Now itâs aâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Marc de Garidel, Abivax | How to make two billion đ¶ exits ("smoothly") | E09
1:11:33
1:11:33
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:11:33
Today, Iâm in Paris (đ«đ·) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success.đ ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO âŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Mike Ward | The Best and the Worst since the 80s in EUÂ Biotech | E08
1:44:25
1:44:25
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:44:25
Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s.đ ABOUT THE SPEAKERMike has been in biotech content since the birth of the industry in the 80s. He has worked at BioCentury, Informa/Scrip and now ClarivateâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Agnete Fredriksen, Nykode | Being one of the top 50 women in đȘđș bio | E07
1:21:51
1:21:51
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:21:51
Weâre live from Oslo đłđŽ to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. đ ABOUT THE SPEAKERAgnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designeâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Rodger Novak, CRISPR Tx | Bringing the first CRISPR drug to the market | E06
1:12:03
1:12:03
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:12:03
Biotech great Rodger Novak, Co-Founder and Chairman of CRISPR Tx joins us on the show. In this episode, we chat about bringing the first CRISPR drug to the market and why he thinks everything is wrong in bio in Europe besides science. Rodgersâ is a name everyone should know, having made it big in the global biotech scene. I first interviewed him baâŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Johannes Fruehauf, BioLabs | Reinventing Incubators For Bio Startups | E05
1:28:43
1:28:43
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:28:43
Weâre back live and in Paris đ«đ· with our next guest, Johannes Fruehauf. We talk about reinventing the co-working labs for biotech startups, the difficulties of doing business in Europe, profitability in biotech, and much more (see timestamps below). đ ABOUT THE SPEAKER Johannes is the President, CEO, and founder of BioLabs, the biggest âincubatorâ,âŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Bernat Olle, Vedanta | Where is the Microbiome Industry Now | E04
1:21:51
1:21:51
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:21:51
In a virtual special, we welcome Bernat Olle to the show. We discuss the microbiome space, including Vedantaâs upcoming Phase 3, and how it feels to be a European founder in Boston. Bernat is the CEO and co-founder of Boston-based Vedanta Biosciences, one of the leading microbiome companies. Theyâve had a positive Phase 2 trial and recently raised âŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Ingmar Hoerr, CureVac | Founding a $20B Biotech and Almost Dying as CEO | E03
2:31:51
2:31:51
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
2:31:51
Itâs a treat to welcome Ingmar Hoerr on the show. We chat about building a 20B dollar biotech startup, almost dying on the job, and why people skills are so important in biotech. Ingmar is a pioneer in the EU biotech scene, revolutionizing drug development with mRNA therapeutics. He and his team created the initial technology used in mRNA vaccines âŠ
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Werner Lanthaler, Evotec | Leading AI in Biotech | E02
1:22:19
1:22:19
SpÀter Spielen
SpÀter Spielen
Listen
GefÀllt mir
Geliked
1:22:19
It's great to have Werner Lanthaler, the CEO of Evotec, one of the largest biotech research companies in Europe/the world, on the show. We have known each other for almost ten years now. He's not only sharp but also friendly and easy to talk to. In this episode, we chat about leading AI in biotech, the sharing economy in the industry, how to be autâŠ
…
continue reading
For our first episode, we catch up with Antoine Papiernik, the chairman of Sofinnova partners, one of the top EU biotech VC funds. We chat about building billion-euro biotechs in Europe, being listed on the Midas list (without letting it go to your head), the importance of being good at selling, being lucky, and how to balance all this with family âŠ
…
continue reading